Published in Eur J Clin Pharmacol on January 03, 2008
Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo) (2011) 0.97
Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. Antimicrob Agents Chemother (2009) 0.88
Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature (1953) 47.27
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 32.05
Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA (1997) 13.66
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol (2002) 2.15
Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf (2006) 2.01
Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract (2005) 1.98
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol (2001) 1.88
A new cytochrome in liver microsomes. J Biol Chem (1962) 1.84
Polypharmacy and hospitalization among older home care patients. J Gerontol A Biol Sci Med Sci (2000) 1.84
Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med (1965) 1.67
Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep (2006) 1.55
Reasons provided by prescribers when overriding drug-drug interaction alerts. Am J Manag Care (2007) 1.48
Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther (2002) 1.32
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther (2007) 1.29
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica (2006) 1.24
Cytochrome P-450 of liver microsomes--one pigment or many. Biochem Biophys Res Commun (1968) 1.09
Hospital admissions due to adverse drug reactions: a comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol (1980) 1.04
Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet (2006) 1.04
Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev Mol Diagn (2007) 1.02
Griseofulvin-phenobarbital interaction in man. JAMA (1970) 1.01
Prediction of maximum exposure in poor metabolizers following inhibition of nonpolymorphic pathways. Curr Drug Metab (2006) 0.77
Systematic screening for pharmacokinetic interactions during drug development. Int J Clin Pharmacol Ther (1996) 0.77
[Drug interactions. Mechanisms and clinical relevance]. Internist (Berl) (2003) 0.77
What is the true risk of a pharmacokinetic drug-drug interaction? Eur J Clin Pharmacol (2007) 0.75
High-throughput lead finding and optimisation for GPCR targets. Ernst Schering Found Symp Proc (2006) 0.75
[Experimental studies in humans on the synergistic action of prednisolone and phenylbutazone]. Arzneimittelforschung (1965) 0.75
The actions and interactions of drugs: the therapeutic significance of enzyme induction. Trans St Johns Hosp Dermatol Soc (1967) 0.75
Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. Clin Pharmacol Ther (1999) 0.75
Seldane warnings. Posit Aware (1998) 0.75
Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol (1992) 0.75